Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Arch Therapeutics, Inc.

  • Terrence Norchi, Arch Therapeutics, Inc.

Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care. Arch is developing products based on an innovative self-assembling barrier technology platform with the goal of making care faster and safer for patients. Arch's development stage product candidates include the AC5™ Topical Gel and the AC5™ Surgical Hemostatic Device.

  • Date:Monday, February 11
  • Time:2:15 PM - 2:30 PM
  • Room:Gramercy
  • Location:7th Floor
  • Session Type:Company Presentation
  • Submission ID:23541
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Goal for Presentation:Corporate Update
  • Company Website:www.archtherapeutics.com
  • Company HQ City:Framingham
  • Company HQ State:Massachusetts
  • Company HQ Country:United States
  • Ticker:ARTH
  • Exchange:OTC
  • CEO/Top Company Official:Terrence W Norchi
  • Year Founded:2006
  • Main Therapeutic Focus:Medical Devices
  • Lead Product in Development:AC5 (TM)
  • Development Phase of Primary Product:Other/Not Applicable
  • Number Of Unlicensed Products (For Which You Are Seeking Partners):Multiple
Speakers
Terrence Norchi
Arch Therapeutics, Inc.
Back